Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02271243 · ClinicalTrials.gov registry record
Using Microbial Genomics to Elucidate the Source of Central-line Associated Bloodstream Infections
A clinical trial, sponsored by Boston Children's Hospital.
- Recruiting
- Registry status
- 60
- Enrollment target
NCT02271243 is a clinical trial that is actively recruiting participants, run by Boston Children's Hospital. The registered enrollment target is 60 participants.
The verdict
NCT02271243 is actively recruiting participants, sponsored by Boston Children's Hospital.
- RECRUITING
- Registry status
- 60 participants
- Enrollment target
Study Summary
Central line-associated bloodstream infections (CLABSIs) are the most common healthcare-associated infection in children and are associated with morbidity and mortality. This study will attempt to identify the source of bloodstream infections (BSIs) in children with CLABSI because we hypothesize that many of the BSIs that are currently classified as CLABSIs are actually laboratory-confirmed bloodstream infections (LCBI) that may be a result of mucosal barrier injury (MBI), also known as MBI-LCBI. In order to study this, we will isolate bacteria from multiple body sites of children that have BSI in order to compare these bacteria to the strain growing in their blood using whole-genome DNA sequencing. We will also evaluate biomarkers of MBI of the respiratory tract and GI tract.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2014-11 |
| Est. Completion | 2027-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02271243
The ClinicalTrials.gov registry entry for NCT02271243 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02271243 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02271243 about?
NCT02271243 is a clinical study titled "Using Microbial Genomics to Elucidate the Source of Central-line Associated Bloodstream Infections". Central line-associated bloodstream infections (CLABSIs) are the most common healthcare-associated infection in children and are associated with morbidity and mortality. This study will attempt to identify the source of bloodstream infections (BSIs) in children with CLABSI because we hypothesize tha...
What is the current status of trial NCT02271243?
This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2014-11. Estimated completion is 2027-12.
Who is sponsoring clinical trial NCT02271243?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.